Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Francesc Bosch

23PUBLICATIONS

165CO-AUTHORS

Medical mycologyEpigenetics (incl. genome methylation and epigenomics)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (23)

Sort by Publication Date:

|Apr 30, 2026

How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

|Jan 23, 2026

Exploring the synergy between telomere length and genomic complexity in CLL.

Silvia Ramos-Campoy, Anna Puiggros, Joanna Kamaso

|Oct 20, 2025

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Martin Hutchings, Anna Sureda, Francesc Bosch

|Jun 06, 2025

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Jeff P Sharman, Talha Munir, Sebastian Grosicki

|May 07, 2025

Myelodysplastic neoplasms with ring sideroblasts without SF3B1 mutations in adults: enrichment of germline variants in congenital sideroblastic anemia genes.

Sandra Novoa-Jáuregui, Sandra Huber, Maria Gabarrós-Subirà

|Apr 24, 2025

ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.

Birna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton

Pageof 4

Frequent Collaborators

4 joint publications

David Valcarcel

3 joint publications

Pere Barba

3 joint publications

Lihua E Budde

3 joint publications

Ian W Flinn

3 joint publications

Claudia Haferlach

3 joint publications

Matthew J Matasar

3 joint publications

Guillermo Villacampa

2 joint publications

Olga Salamero

2 joint publications

Giuseppe Gritti

2 joint publications

Marta Crespo

Frequent Collaborators

4 joint publications

David Valcarcel

3 joint publications

Pere Barba

3 joint publications

Lihua E Budde

3 joint publications

Ian W Flinn

Top Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on : Sep 20, 2016

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Published on : Jan 17, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

See more related videos

Top Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on : Sep 20, 2016

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells

Published on : Jan 17, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

See more related videos